Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 2

Status

Recruiting 2Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4

Conditions

Melanoma 4Carcinoma, Basal Cell 4Sarcoma, Kaposi 1Carcinoma, Squamous Cell 1Carcinoma, Merkel Cell 1Carcinoma 1

Interventions

pembrolizumab 166Nivolumab 111Ipilimumab 93Dacarbazine 44trametinib 36dabrafenib 34Vemurafenib 33binimetinib 23atezolizumab 23Temozolomide 21cemiplimab 18Paclitaxel 18encorafenib 17spartalizumab 16cobimetinib 15Carboplatin 14talimogene laherparepvec 13Cisplatin 13Cyclophosphamide 12lenvatinib 10Pemetrexed 10Gemcitabine 10Docetaxel 10durvalumab 9Drug Therapy 9Bevacizumab 9tremelimumab 8Injections 8Albumin-Bound Paclitaxel 8130-nm albumin-bound paclitaxel 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Melanoma × daromun × Clear all
NCT03567889 2025-12-17

NeoDREAM

Philogen S.p.A.

Phase 3 Recruiting
186 enrolled
Dermatologic

Melanoma

NCT06284590 2024-10-26

INTACT/MeRCI

Philogen S.p.A.

Phase 2 Recruiting
162 enrolled
Dermatologic

Melanoma

NCT02938299 2024-09-19

Pivotal

Philogen S.p.A.

Phase 3 Active not recruiting
214 enrolled
Dermatologic

Melanoma

NCT02076633 2015-05-27

Intratumoral Administration of L19IL2/L19TNF

Philogen S.p.A.

Phase 2 Completed
21 enrolled
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡